Janssen
Janssen’s study for nipocalimab as indicated for EOS-HDFN published in The New England Journal of Medicine
August 9, 2024Research and Development Haematology, Janssen, New England Journal of Medicine, Obstetrics & Gynaecology, foetus, newborn, women's health
Johnson & Johnson company Janssen has announced that the results from its phase 2 trial into nipocalimab have been published …
GSK enters agreement for license for JNJ-3089 for development of bepirovirsen
November 2, 2023Medical Communications Arrowhead Pharmaceuticals, GSK, Infections and infestations, Janssen, hepatitis B
GSK and Arrowhead Pharmaceuticals have announced that they have come to an agreement with Janssen Pharmaceuticals, a Johnson & Johnson …
Janssen and Sanofi enter agreement for potential vaccine programme
October 5, 2023Business Services Immunology, Janssen, Sanofi, e coli, vaccines
Janssen Pharmaceuticals, a Johnson & Johnson company, has announced a development and commercialisation agreement with Sanofi for Janssen’s extraintestinal pathogenic …
Janssen submits sNDA to FDA for full approval of Balversa
August 29, 2023Research and Development Balversa, FDA, Janssen, Oncology
The Janssen Pharmaceutical Companies of Johnson & Johnson has announced the submission of a supplemental New Drug Application (sNDA) to …
FDA approved Janssen’s Akeega for prostate cancer treatment
August 14, 2023Research and Development Akeega, FDA, J&J, Janssen, Oncology, prostate cancer
The Janssen Pharmaceutical companies of Johnson & Johnson have announced that the US Food and Drug Administration (FDA) has approved …
FDA approves Talvey for the treatment of heavily pretreated multiple myeloma
August 11, 2023Medical Communications FDA, J&J, Janssen, Oncology, Talvey, multiple myeloma
The Janssen Pharmaceutical companies of Johnson & Johnson has announced that the US Food and Drug Administration (FDA) has granted …
Nanobiotix announces license agreement with Janssen for development and commercialisation of new cancer treatment
July 10, 2023Sales and Marketing Cancer, Janssen, License Agreement, Oncology, nanobiotix
Nanobiotix has announced a global licensing, co-development and commercialisation agreement with Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies …
Janssen CLL treatment combination sees success in trials
June 14, 2021Sales and Marketing CLL, Janssen
Janssen has announced positive data from its Phase III GLOW study, with the combination of imbruvica (ibrutinib) plus venetoclax (I+V) …
NICE recommends Janssen’s active psoriatic arthritis drug
May 28, 2021Medical Communications Janssen, NICE, UK, arthritis
NICE have released a Final Appraisal Document (FAD) recommending Janssen’s tremfya (guselkumab) as a new option for treating active psoriatic …
Janssen sees promising PRO data for prostate cancer therapy
May 27, 2021Janssen, prostate cancer
Janssen has announced patient-reported outcomes (PRO) data from the pre-specified final analysis of their Phase III TITAN study in patients …
Janssen submits MAA to EMA for novel CAR-T cell therapy
May 5, 2021Research and Development EMA, EU, Janssen, multiple myeloma
Janssen have submitted a Marketing Authorisation Application (MAA) to the EMA seeking approval of cilta-cel, an investigational B cell maturation …
J&J vaccine halted in US due to blood clots
April 14, 2021Research and Development CDC, COVID-19 vaccine, FDA, Janssen, Johnson & Johnson, pharma, pharma news
The CDC and FDA have recommended a pause in the use of the Johnson & Johnson COVID-19 vaccine in the …
Janssen agrees $780 million deal for authorisation of Cidara flu treatment
April 6, 2021Manufacturing and Production Janssen, cidara, influenza
Janssen has struck a deal worth up to $780 million with Cidara Therapeutics for exclusive worldwide rights to Cidara’s CD388 …
J & J to ship up to 400 million vaccines to Africa
March 30, 2021Manufacturing and Production COVAX, COVID-19, COVID-19 vaccine, Janssen, Johnson & Johnson
Johnson & Johnson has reached an agreement to ship as many as 400 million doses of their COVID-19 vaccine to …
Janssen’s multiple sclerosis treatment recommended by EMA
March 29, 2021Sales and Marketing CHMP, EMA, Janssen, Johnson & Johnson, PONVORY, multiple sclerosis
Janssen’s PONVORY therapy for the treatment of adults with relapsing forms of multiple sclerosis (MS) has been recommended by the …
Latest content
Five Facts about cardiovascular disease
